aTyr Pharma, Inc.
ATYR
$0.53
-$0.03-5.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 27.48% | 6.71% | -49.16% | -19.78% | 3.94% |
| Total Depreciation and Amortization | 2.87% | 39,500.00% | 0.26% | 1.04% | -50.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 60.70% | 285.65% | 462.41% | 10,675.00% | 1,076.12% |
| Change in Net Operating Assets | -101.08% | -66.67% | 14.39% | 197.48% | 79.23% |
| Cash from Operations | 18.83% | 7.13% | -55.62% | 32.06% | 31.10% |
| Capital Expenditure | -- | -24.00% | -146.67% | -12.50% | -- |
| Sale of Property, Plant, and Equipment | -- | 71.43% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 363.17% | 371.34% | -213.25% | -50.86% | -230.10% |
| Cash from Investing | 360.05% | 370.22% | -213.55% | -50.94% | -225.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.40% | -8.59% | -8.80% | -8.13% | -8.26% |
| Issuance of Common Stock | -- | -99.96% | 148,665.00% | 33.33% | 138.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.76% | -100.70% | 28,306.67% | 33.56% | 140.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.88% | 1,188.89% | -339.93% | 2,375.39% | 92.43% |